natgillin/translations-raw huggingface dataset:
This included published literature (SIPPET study6), data generated in individual clinical trials and a range of observational studies submitted by the marketing authorisation holders, including the data generated in large multicentre cohort studies, data submitted by the national competent authorities of the EU Member States as well as responses provided by the Authors of the SIPPET study. 
To je obsegalo objavljeno literaturo (študija SIPPET6), podatke, pridobljene v posameznih kliničnih preskušanjih, in vrsto opazovalnih študij, ki so jih predložili imetniki dovoljenja za promet, vključno s podatki, pridobljenimi v velikih multicentričnih kohortnih študijah, podatke, ki so jih predložili pristojni nacionalni organi držav članic EU, ter odzive avtorjev študije SIPPET.
In patients where immune tolerance was achieved the bleedings could be prevented or controlled with KOGENATE Bayer again, and the patients could continue with prophylactic treatment as maintenance therapy. 
Pri bolnikih, pri katerih je bila imunska toleranca dosežena, je bilo mogoče krvavitev znova preprečiti ali nadzorovati z zdravilom KOGENATE Bayer, bolniki pa so lahko nadaljevali s profilaktičnim zdravljenjem kot vzdrževalnim zdravljenjem.
Frequency, type and severity of adverse reactions in children are expected to be the same as in all population groups except for the inhibitor formation. 
Pričakuje se, da so pogostnost, vrsta in resnost neželenega učinka pri otrocih enaki kot pri ostalih populacijah bolnikov, razen glede nastanka zaviralcev.
patients (<6 years, male, severe haemophilia A, no previous treatment with any FVIII concentrate or only minimal treatment with blood components) were included from 42 sites. 
Vključeni so bili primerni bolniki (< 6 let, moški, huda hemofilija A, brez predhodnega zdravljenja s katerim koli koncentratom FVIII ali le minimalno zdravljeni s krvnimi komponentami) iz 42 ustanov.
If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user. 
Če se zdravila ne uporabi takoj po rekonstituciji, je za trajanje in pogoje shranjevanja pred uporabo odgovoren uporabnik.
There are no fertility data available. 
Podatkov o vplivu na plodnost ni.
Your doctor will tell you, how often and at what intervals this medicine is to be administered. 
Zdravnik vam bo svetoval, kako pogosto in v kakšnih presledkih morate uporabljati to zdravilo.
Repeat infusion every 12 - 24 hours for 3 - 4 days or more until pain and disability are resolved. 
Ponavljajte vsakih 12 do 24 ur, 3 do 4 dni ali več, dokler ne mineta bolečina in onesposobljenost.
Do not remove the adapter from the plastic housing. 
Ne odstranite adapterja s plastičnega ohišja.
KOGENATE Bayer has no influence on the ability to drive or to use machines. 
Zdravilo KOGENATE Bayer nima vpliva na sposobnost vožnje in upravljanja strojev.
FVIII replacement therapy can be generally categorised into two broad classes of products; plasma derived (pdFVIII) and recombinant (rFVIII) FVIII. 
Nadomestno zdravljenje s FVIII je na splošno mogoče razvrstiti v dve široki skupini izdelkov; plazemski (pdFVIII) in rekombinantni (rFVIII) FVIII.
The reconstituted medicinal product is a clear and colourless solution. 
Rekonstituirano zdravilo je bistra in brezbarvna raztopina.
The PRAC also considered interim results submitted by the MAHs from ongoing studies from CSL (CRD019_5001) and Bayer (Leopold KIDS, 13400, part B.). 
Odbor PRAC je obravnaval tudi vmesne rezultate iz študij, ki potekajo, in sta jih predložila imetnika dovoljenj za promet z zdravilom CSL (CRD019_5001) in Bayer (Leopold KIDS, 13400, del B.).
Data show that KOGENATE Bayer has been used to induce immune tolerance. 
Podatki kažejo, da se zdravilo KOGENATE Bayer uporablja za indukcijo imunske tolerance.
Inhibitors developed in 29 of the 125 patients treated with pdFVIII (20 patients had high-titre inhibitors) and in 47 of the 126 patients treated with rFVIII (30 patients had high-titre inhibitors). 
Zaviralci so se pojavili pri 29 od 125 bolnikov, zdravljenih s pdFVIII (20 bolnikov je imelo visoke titre zaviralcev), in pri 47 od 126 bolnikov, zdravljenih z rFVIII (30 bolnikov je imelo visoke titre zaviralcev).
Driving and using machines No effects on ability to drive or use machines have been observed. 
Vpliv na sposobnost upravljanja vozil in strojev Vpliva na sposobnost vožnje in upravljanja strojev niso opazili.
• Individual studies have identified a wide range of inhibitor development across products, but the direct comparability of study results is questionable based on diversity of study methods and patient populations over time. 
• v posameznih študijah so odkrili širok razpon pojavljanja zaviralcev med zdravili, vendar je neposredna primerljivost rezultatov študije vprašljiva zaradi razlik v metodologiji študij in populacijah bolnikov v odvisnosti od časa;
Rare / not known 
Zelo redki / neznana pogostnost
Treatment of congenital haemophilia is currently based on prophylactic or on-demand replacement therapy with coagulation factor VIII (FVIII). 
Zdravljenje kongenitalne hemofilije trenutno temelji na profilaktični ali nadomestni terapiji na zahtevo s koagulacijskim faktorjem VIII (FVIII).
Set the syringe aside for further use. 
Injekcijsko brizgo dajte na stran za kasnejšo uporabo.
Immune Tolerance Induction (ITI) 
Indukcija imunske tolerance (ITI - Immune Tolerance Induction)
Example: for a 75 kg patient with a clearance of 3 mL/h/kg, the initial infusion rate would be 3 IU/h/kg to achieve a FVIII level of 100%. 
Primer: za bolnika težkega 75 kg z očistkom 3 ml/h/kg bi bila začetna hitrost infundiranja 3 i.e./h/kg, da bi dosegli 100 % raven FVIII.
Individual patients may vary in their response to factor VIII, demonstrating different half-lives and recoveries. 
Posamezni bolniki se lahko različno odzivajo na faktor VIII, kar se kaže v različnem razpolovnem času zdravila in času okrevanja.
If you are using KOGENATE Bayer to prevent bleeding (prophylaxis), your doctor will calculate the dose for you. 
Če zdravilo KOGENATE Bayer uporabljate za preprečevanje krvavitev (profilakso), bo velikost odmerka za vas izračunal zdravnik.
• Patient-related risk factors include type of F8 gene mutation, severity of haemophilia, ethnicity, family history of inhibitor development and possibly HLA-DR (Human Leukocyte Antigen - antigen D Related) constitution. 
• dejavniki tveganja, povezani z bolniki, obsegajo vrsto mutacije gena F8, resnost hemofilije, etnično pripadnost, družinsko anamnezo pojava zaviralcev in morda sestavo HLA-DR (humani levkocitni antigen - povezan z antigenom D);
Prior to the current referral, it was noted that PRAC had already considered the implications of the RODIN/Pednet, the UKHCDO and the FranceCoag studies for the EU marketing authorisations for FVIII products. 
Pred trenutno napotitvijo je bilo ugotovljeno, da je odbor PRAC že preučil posledice študij RODIN/Pednet, UKHCDO in FranceCoag za dovoljenja za promet z zdravili s FVIII v EU.
Some experimental studies have suggested a role for VWF in protecting FVIII epitopes from recognition by the antigen-presenting cells, thereby reducing immunogenicity, although this remains theoretical. 
Nekatere eksperimentalne študije so nakazale, da VWF prepreči antigenpredstavitvenim celicam, da bi prepoznale epitope FVIII, s čimer se imunogenost zmanjša, čeprav je to še vedno teoretično.
The reconstituted solution must be used within 3 hours. 
Rekonstituirano raztopino je treba uporabiti v 3 urah.
The risk of inhibitor development is multifactorial (aside from any putative product-specific risk), and such studies have not always been able to collect information on relevant covariates and to adjust the analyses accordingly; residual confounding is inevitably a significant uncertainty. 
Tveganje za pojav zaviralca je posledica več dejavnikov (poleg vseh domnevnih tveganj, povezanih s posameznim zdravilom) in takšne študije niso vedno zmogle zbrati informacij o ustreznih kovariatah ter ustrezno prilagoditi analize; preostale begave spremenljivke so neizogibna velika negotovost.
You are filtering by following the reconstitution and/or administration steps as described below. 
Pri filtriranju upoštevajte postopek za rekonstitucijo in/ali uporabo, kot je opisano spodaj.
The listed warnings and precautions apply both to adults and children. 
Navedena opozorila in previdnostni ukrepi veljajo za odrasle in otroke.
The product contains traces of mouse and hamster proteins and human proteins other than factor VIII (see section 5.1). 
Zdravilo vsebuje sledi beljakovin miši in hrčkov ter poleg faktorja VIII tudi sledi humanih beljakovin (glejte poglavje 5.1).
The statistical concerns include the fact that no pre-specified primary analysis has been published and the fact that the study was stopped early following the publication of the RODIN study indicating that Kogenate FS might be associated with an increased risk of inhibitor formation. 
Statistični zadržki obsegajo dejstvo, da ni bila objavljena predhodno določena primarna analiza in dejstvo, da je bila študija predčasno ustavljena po objavi študije RODIN, ki je pokazala, da bi lahko bilo zdravilo Kogenate FS povezano s povečanim tveganjem za pojav zaviralcev.
No conclusions can be drawn on any role of VWF in protecting against inhibitor development. 
Ni mogoče sklepati o vlogi VWF pri zaščiti pred pojavom zaviralcev.
This product is indicated for adults, adolescents and children of all ages. 
Zdravilo je indicirano za odrasle, mladostnike in otroke vseh starosti.
Information submitted by the lead authors of the SIPPET study during the course of the referral was also taken into consideration by PRAC in reaching its conclusion. 
Informacije, ki so jih predložili vodilni avtorji študije SIPPET med napotitvijo, je odbor PRAC upošteval pri oblikovanju mnenja.
Remove the cap from the powder vial by gently moving it from side to side several times, whilst at the same time pulling upwards. 
Zaporko na viali s praškom odstranite tako, da jo večkrat rahlo premaknete z ene na drugo stran, istosočasno pa jo vlecite navzgor.
B CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2). 
B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE Predpisovanje in izdaja zdravila je le s posebnim režimom (glejte Prilogo I: Povzetek glavnih značilnosti zdravila, poglavje 4.2).
After the initial 24 hours of continuous infusion, the clearance should be recalculated every day using the steady state equation with the measured FVIII level and the rate of infusion using the following equation: clearance = infusion rate/actual FVIII level. 
Po začetni 24-urni kontinuirani infuziji, je treba vsak dan preračunati očistek na podlagi izmerjene ravni FVIII in hitrosti infundiranja z uporabo naslednje enačbe: očistek = hitrost infundiranja/dejanska raven FVIII.
The calculation of the required dose of factor VIII is based on the empirical finding that 1 International Unit (IU) factor VIII per kg body weight raises the plasma factor VIII activity by 1.5% to 2.5% of normal activity. 
Izračun potrebnega odmerka faktorja VIII temelji na empirični ugotovitvi, da ena mednarodna enota (i.e.) faktorja VIII na kilogram telesne mase, poveča aktivnost faktorja VIII v plazmi za 1,5 - 2,5 % normalne aktivnosti.
Having considered the abovementioned results from SIPPET, the published literature and all the information submitted by the MAHs, as well as the views expressed by experts expressed at the ad-hoc expert meeting, the PRAC concluded that: 
Ob upoštevanju zgoraj omenjenih rezultatov študije SIPPET, objavljene literature, vseh informacij, ki so jih predložili imetniki dovoljenj za promet z zdravilom, in mnenj strokovnjakov, izraženih na ad-hoc strokovnem sestanku, je odbor PRAC sklenil, da:
Medical devices for reconstitution and administration are provided with each package of this medicine. 
Pribor za rekonstitucijo in uporabo je priložen v vsakem pakiranju tega zdravila.
After reconstitution, from a microbiological point of view, the product should be used immediately. 
Z mikrobiološkega vidika je treba zdravilo uporabiti takoj po rekonstituciji.
Warm the unopened powder vial and the solvent syringe in your hands until they feel as warm as your hands. 
Z rokami ogrejte neodprto vialo s praškom in injekcijsko brizgo z vehiklom dokler nista tako topli kot vaše roke.
These treatments should be prescribed by doctors with experience in the care of patients with haemophilia A. Speak to your doctor if you would like further information on this. 
Dodatno zdravljenje vam mora predpisati zdravnik, ki ima izkušnje z zdravljenjem bolnikov s hemofilijo A. Posvetujte se z zdravnikom, če v zvezi s tem potrebujete še kakršne koli dodatne informacije.
The expert group suggested that further data are needed to establish if there are clinically relevant differences in frequency of inhibitor development between different factor VIII products and that, in principle, such data should be collected separately for individual products, as degree of immunogenicity will be difficult to generalise across the classes of products (i.e. recombinant vs. plasma-derived). 
Strokovna skupina je predlagala, da so potrebni dodatni podatki za ugotavljanje, ali obstajajo klinično pomembne razlike v pogostnosti pojava zaviralcev med različnimi zdravili s faktorjem VIII in da bi bilo treba takšne podatke načeloma zbirati ločeno za posamezna zdravila, ker bo stopnjo imunogenosti težko posplošiti po razredih zdravil (npr. rekombinantni faktor in faktor, pridobljen iz plazme).
Importantly, the EU SmPCs do not include modified prophylaxis (as defined in the SIPPET study) as an authorised posology, and the impact of the apparent imbalance in the unspecified other combinations of treatment modality on the SIPPET findings is unclear. 
Pomembno je, da povzetki glavnih značilnosti zdravila v EU ne vključujejo modificirane profilakse (kot je opredeljena v študiji SIPPET) kot dovoljene sheme odmerjanja, zato učinek očitnega neravnovesja v neopredeljenih drugih kombinacijah načina zdravljenja na ugotovitve študije SIPPET ni jasen.
The following table provides a guide for factor VIII minimum blood levels. 
V naslednji preglednici so navodila glede minimalnih ravni faktorja VIII v krvi.
Therefore, it remains uncertain whether the same differential risk of inhibitor development observed in the SIPPET study would be apparent in patient populations treated in routine care in other countries where the modality of treatment (i.e. primary prophylaxis) is different from that in the study. 
Posledično še vedno obstaja negotovost, ali bi bila razlika v tveganju za pojav zaviralcev, ugotovljenem v študiji SIPPET, razvidna pri bolnikih, zdravljenih z rutinsko oskrbo, v drugih državah, kjer je način zdravljenja (tj. primarna profilaksa) drugačen od tistega v študiji.
Thrombin then converts fibrinogen into fibrin and a clot can be formed. 
Nato trombin pretvori fibrinogen v fibrin, ki omogoča nastanek krvnega strdka.
• The FVIII products are heterogenous, and the plausibility of different rates of inhibitor development between individual products cannot be excluded. 
• zdravila s FVIII so heterogena in verjetnosti različnih stopenj pojavljanja zaviralcev med posameznimi zdravili ni mogoče izključiti;
The degree and duration of aPTT normalisation observed after administration of KOGENATE Bayer is similar to that achieved with plasma-derived factor VIII. 
Stopnja in trajanje normalizacije APTČ sta po uporabi zdravila KOGENATE Bayer podobna kot pri faktorju VIII, pridobljenim iz plazme.
Inhibitors developed in 76 patients, 50 of whom had high-titre inhibitors (≥5 BU). 
Zaviralci so se pojavili pri 76 bolnikih, od katerih jih je 50 imelo visoke titre zaviralcev (≥ 5 BU).
This result is similar to the reported values for factor VIII derived from human plasma. 
Rezultati so podobni kot pri faktorju VIII, pridobljenim iz humane plazme.
What KOGENATE Bayer is and what it is used for What you need to know before you use KOGENATE Bayer How to use KOGENATE Bayer Possible side effects 
Kaj je zdravilo KOGENATE Bayer in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo KOGENATE Bayer Kako uporabljati zdravilo KOGENATE Bayer Možni neželeni učinki
2 alcohol swabs for single use 
2 alkoholna tampona za enkratno uporabo
If you want to stop using KOGENATE Bayer Do not stop using KOGENATE Bayer without consulting your doctor. 
Če želite prenehati uporabljati zdravilo KOGENATE Bayer Ne prenehajte uporabljati zdravila KOGENATE Bayer, ne da bi se prej posvetovali z zdravnikom.
The most serious side effects are hypersensitivity reactions or anaphylactic shock (rare side effect). 
Najbolj resni neželeni učinki so preobčutljivostne reakcije ali anafilaktični šok (redek neželeni učinek).
Given the detailed grounds provided by the MAH, the PRAC carried out a new assessment of the available data in the context of the re-examination. 
Glede na podrobno opisane razloge imetnika dovoljenja za promet je odbor PRAC v okviru ponovne proučitve znova ocenil razpoložljive podatke.
• Treatment-related factors include intensity of exposure, number of exposure days (EDs), on demand treatment posing a greater risk than prophylaxis, particularly in the context of danger signals such as trauma or surgery, and young age at first treatment poses a higher risk. 
• dejavniki, povezani z zdravljenjem, vključujejo intenzivnost izpostavljenosti, število dni izpostavljenosti, nižjo starost pri prvem zdravljenju in zdravljenje na zahtevo ter predstavljajo večje tveganje kot profilaksa, zlasti v zvezi z opozorilnimi signali, kot so travma ali kirurški poseg.
• The PRAC considered the procedure under Article 31 of Directive 2001/83/EC resulting from pharmacovigilance data, for human plasma derived and recombinant coagulation factor VIII containing medicinal products (see Annex I and Annex A). 
• odbor PRAC je upošteval napotitev v skladu s členom 31 Direktive 2001/83/ES, ki je bila na podlagi farmakovigilančnih podatkov predložena za zdravila, ki vsebujejo rekombinantni koagulacijski faktor VIII (glejte prilogo I in prilogo A);
Clinical discussion 
Klinična razprava
Factor VIII activity in plasma is expressed either as a percentage (relative to normal human plasma) or in International Units (relative to the International Standard for factor VIII in plasma). 
Aktivnost faktorja VIII v plazmi je izražena v odstotkih (glede na aktivnost v normalni humani plazmi) ali v mednarodnih enotah (glede na mednarodni standard za faktor VIII v plazmi).
If a further dose needs to be administered, use a new syringe with product reconstituted as described above. 
Če je potreben dodaten odmerek zdravila, uporabite novo injekcijsko brizgo z zdravilom, rekonstituiranim po postopku, ki je opisan zgoraj.
* Frequency is based on studies with all FVIII products which included patients with severe haemophilia A. PTPs = previously-treated patients, PUPs = previously untreated patients 
* Pogostnost temelji na študijah z vsemi zdravili s FVIII, ki so vključevale bolnike s hudo hemofilijo A. PZB = predhodno zdravljeni bolniki, PNB = predhodno nezdravljeni bolniki
Life threatening haemorrhages (such as intracranial bleed, throat bleed, severe abdominal bleed) 
življenjsko ogrožajoče krvavitve (npr. intrakranialna krvavitev, krvavitev v grlo, huda abdominalna krvavitev)
Additional pharmacokinetic parameters for KOGENATE Bayer for bolus injection are: mean residence time [MRT (0-48)] of about 22 hours and clearance of about 160 mL/h. 
Dodatni farmakokinetični parametri za bolusno injekcijo zdravila KOGENATE Bayer so: povprečni čas zadrževanja [PČZ (0 - 48)] približno 22 ur in očistek približno 160 ml/h.
One International Unit (IU) of factor VIII activity is equivalent to that quantity of factor VIII in one mL of normal human plasma. 
Ena mednarodna enota (i.e.) aktivnosti faktorja VIII ustreza količini faktorja VIII v enem mililitru normalne humane plazme.
Further to the assessment of the totality of the responses submitted by the MAH for susoctocog alfa (Obizur), the PRAC is of the opinion that the outcome of this article 31 referral procedure does not apply to this product in view of the indication of Obizur (acquired haemophilia A due to inhibitory antibodies to endogenous FVIII) and the different target population. 
Poleg ocene vseh odgovorov, ki jih je predložil imetnik dovoljenja za promet s susoktokogom alfa (Obizur), je odbor PRAC menil, da izid tega napotitvenega postopka v skladu s členom 31 ne velja za omenjeno zdravilo zaradi indikacije za zdravilo Obizur (pridobljena hemofilija A zaradi inhibitornih protiteles proti endogenemu FVIII) in drugačne ciljne populacije.
This trial, known as the SIPPET study (“Survey of Inhibitors in PlasmaProduct Exposed Toddlers”) was conducted to evaluate the relative risk of inhibitors in patients treated with pdFVIII compared to rFVIII. 
To preskušanje, imenovano študija SIPPET („Študija zaviralcev pri malih otrocih, izpostavljenih zdravilom iz plazme“), je bilo opravljeno za ocenitev relativnega tveganja za zaviralce pri bolnikih, zdravljenih s pdFVIII, v primerjavi z rFVIII.
Although this could not have been prevented, an early termination of an open label trial raises the possibility of investigator bias and inflation of the probability of detecting an effect that is not present. 
Čeprav tega ni bilo mogoče preprečiti, pri predčasni prekinitvi neslepih preskušanj obstaja možnost napake raziskovalca in povečanja verjetnosti zaznave neobstoječega učinka;
The dose, frequency and duration of the substitution therapy must be individualised according to the patient's needs (weight, severity of disorder of the haemostatic function, the site and extent of the bleeding, the presence of inhibitors, and the factor VIII level desired). 
Odmerek, pogostnost in trajanje nadomestnega zdravljenja je treba prilagoditi potrebam posameznega bolnika (odvisno od telesne mase, stopnje motnje strjevanja krvi, mesta in obsega krvavitve, prisotnosti zaviralcev in od želene ravni faktorja VIII).
Reconstitute the desired amount of product, repeating steps 2 - 9, using a new syringe and connect it to the venipuncture set. 
Za rekonstitucijo želene količine zdravila ponovite korake od 2 do 9, vzemite novo injekcijsko brizgo in jo privijte na pribor za vensko punkcijo.
The formation of inhibitors (antibodies) is a known complication that can occur during treatment with all Factor VIII medicines. 
Nastanek zaviralcev (protiteles) je znan zaplet, ki se lahko pojavi med zdravljenjem z vsemi zdravili s faktorjem VIII.
Benefit -risk balance 
Razmerje med koristmi in tveganji
In relation to section 5.1, any reference to inhibitor development studies in PUPs and PTPs should be deleted unless the studies were conducted in compliance with a Paediatric Investigation Plan or the studies provide robust evidence of a frequency of inhibitors in PUP which is less than ‘very common' or for PTPs which is different from ‘uncommon' (as laid down in the attachments of the PRAC AR). 
V zvezi s poglavjem 5.1 je treba vse sklice na študije pojava zaviralcev pri predhodno nezdravljenih in predhodno zdravljenih bolnikih izbrisati, razen če so bile študije izvedene v skladu z načrtom študij za pediatrično populacijo ali študije zagotavljajo zanesljive dokaze o pogostnosti pojava zaviralcev pri predhodno nezdravljenih bolnikih, ki je manjša kot „zelo pogosti“ ali pri predhodno zdravljenih bolnikih, ki se razlikuje od „občasni“ (kot je določeno v prilogah PRAC AR).
Be sure that the powder is completely dissolved. 
Preverite, če je prašek popolnoma raztopljen.
In the case of the haemorrhagic events listed, the factor VIII activity should not fall below the given level (in % of normal) in the corresponding period: 
V primeru pojava navedenih krvavitev, aktivnost faktorja VIII v določenem obdobju ne sme pasti pod dano raven (% normalne vrednosti):
No additional communication, on risk factors for inhibitor development beyond the product information or any additional risk minimisation measures was recommended. 
Dodatna sporočila o dejavnikih tveganja za pojav zaviralcev, ki presegajo informacije o zdravilu, ali dodatni ukrepe za zmanjšanje tveganja niso bili priporočeni.